Answers are grounded in this paper and cite their sources.
irAEs induced by Immune Checkpoints Inhibitors (ICIs) should improve survival, however the impact of multiple and severe irAEs on treatment response remains unclear. This study aimed to assess the association between irAEs pairs and response in melanoma patients. It was a retrospective observational study using the global database VigiBase, and the french RIC-Mel cohort, including melanoma patients treated with ICIs: anti-CTLA-4 (ipilimumab), anti-PD-1 (nivolumab and pembrolizumab), and anti-LAG-3 (relatlimab), and who experienced at least one irAE. After identifying individual irAEs and their co-occurrences as pairs, their association with treatment response was assessed using logistic regression. We identified 31,981 ICIs-treated patients in VigiBase and 6,362 in RIC-Mel. At least one irAE occurred in 63% of VigiBase cases and 25% of RIC-Mel patients. Among patients with irAEs, 17% in VigiBase and 8% in RIC-Mel, respectively, had experienced at least two. Nearly 300 irAEs pairs were identified, most commonly involving cutaneous, gastrointestinal, endocrine, and musculoskeletal systems. Among patients with two or more irAEs, co-occurring irAEs were associated with a reduced likelihood of reported disease progression in VigiBase (significant for 8 pairs among both all cases and severe cases). In RIC-Mel, no significant associations were found, although about half of pairs with results suggested a potential likelihood of favorable treatment response, involving similar organ systems as in VigiBase. Our results suggest that the emergence of specific irAEs pairs might serve as composite markers of beneficial immune activation and therapeutic efficacy.
No takes yet. Share an insight, caveat, or question.
Hessou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: